# Lapatinib ditosylate

## Tykerb 250mg

| TAH Drug Code      | [OTYK](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OTYK)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | TYKERB in combination with capecitabine is indicated for the treatment of patients with advanced or metastatic breast cancer who have HER2/neu (ErbB2) overexpression and have experienced disease progression after prior treatment with anthracyclines， taxanes， and trastuzumab. TYKERB in combination with an aromatase inhibitor is indicated for the treatment of HER2/neu (ErbB2) overexpressing， hormone receptor-positive metastatic breast cancer in postmenopausal women who have not previously received trastuzumab or an aromatase inhibitor， and who are not planning to undergo chemotherapy. |
| Dosing             | Monitor left ventricular ejection fraction (baseline and periodic) before and during therapy. TYKERB should be taken at least one hour before or one hour after a meal. [Advanced/metastatic breast cancer] 1250 mg (5 tablets) once daily on Days 1-21 continuously in combination with capecitabine 2，000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle. [Hormone receptor (+)， HER2 (+) metastatic breast cancer] 1500 mg (6 tablets) once daily continuously in combination with letrozole 2.5 mg once daily.                            |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Contraindications  | Hypersensitivity to lapatinib ditosylate or to any of the excipients of Tykerb                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Adverse Effects    | Anorexia， diarrhea， nausea， vomiting， rash， fatigue， dyspepsia， dry skin， stomatitis， constipation， abdominal pain， palmar-plantar erythrodysesthesia， mucosal inflammation， pain in extremity， back pain， insomnia， epistaxis， alopecia; decreased LVEF， nail disorders， headache.                                                                                                                                                                                                                                                                                                            |
| Pregnancy          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Lactation          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| More Info          | [UpToDate](https://www.uptodate.com/contents/lapatinib-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

